125 related articles for article (PubMed ID: 22909201)
1. Company Profile: AKESOgen, Inc.
Bouzyk M; Boisjoli R
Pharmacogenomics; 2012 Jul; 13(10):1115-8. PubMed ID: 22909201
[TBL] [Abstract][Full Text] [Related]
2. Company profile: PGXIS Ltd.
McCarthy A
Pharmacogenomics; 2011 Sep; 12(9):1253-6. PubMed ID: 21919604
[TBL] [Abstract][Full Text] [Related]
3. Implications of pharmacogenomics for drug development.
Kirk RJ; Hung JL; Horner SR; Perez JT
Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
[TBL] [Abstract][Full Text] [Related]
4. Company profile: Sequenom, Inc.
Cantor CR
Pharmacogenomics; 2012 Apr; 13(5):529-31. PubMed ID: 22462745
[TBL] [Abstract][Full Text] [Related]
5. Vita Genomics, Inc.
Shih-Hsin Wu L; Su CL; Chen E
Pharmacogenomics; 2007 Jun; 8(6):669-73. PubMed ID: 17559355
[TBL] [Abstract][Full Text] [Related]
6. Génome Québec & Montreal Heart Institute Pharmacogenomics Centre: a translational pharmacogenomics platform--from R&D to the clinic.
Phillips MS; Hihi AK; van Rooij T; Smith AC; James S; Marsh S; Laplante N; Dubé MP; Tardif JC
Pharmacogenomics; 2008 Oct; 9(10):1391-6. PubMed ID: 18855527
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers and personalized therapy in chronic kidney diseases.
Schena FP
Expert Opin Investig Drugs; 2014 Aug; 23(8):1051-4. PubMed ID: 24857812
[TBL] [Abstract][Full Text] [Related]
8. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI.
Wang SJ
Pharm Stat; 2007; 6(4):283-96. PubMed ID: 17957727
[TBL] [Abstract][Full Text] [Related]
9. PhRMA survey of pharmacogenomic and pharmacodynamic evaluations: what next?
Grecco N; Cohen N; Warner AW; Lopez-Correa C; Truter SL; Snapir A; Piccoli SP; Wang D; Westelinck A; Hinman L; Franc MA;
Clin Pharmacol Ther; 2012 Jun; 91(6):1035-43. PubMed ID: 22534869
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics: the promise of personalized medicine for CNS disorders.
de Leon J
Neuropsychopharmacology; 2009 Jan; 34(1):159-72. PubMed ID: 18800072
[TBL] [Abstract][Full Text] [Related]
11. Rubicon Genomics, Inc.
Langmore JP
Pharmacogenomics; 2002 Jul; 3(4):557-60. PubMed ID: 12164778
[TBL] [Abstract][Full Text] [Related]
12. Progress in pharmacogenomics and its promise for medicine.
Blake CA; Sobel BE
Exp Biol Med (Maywood); 2008 Dec; 233(12):1482-3. PubMed ID: 18849537
[TBL] [Abstract][Full Text] [Related]
13. DxS Ltd.
Little S
Pharmacogenomics; 2003 Jan; 4(1):97-101. PubMed ID: 12517290
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics. Going from genome to pill.
Service RF
Science; 2005 Jun; 308(5730):1858-60. PubMed ID: 15976283
[No Abstract] [Full Text] [Related]
15. Golden Helix Pharmacogenomics Days: educational activities on pharmacogenomics and personalized medicine.
Squassina A; Severino G; Grech G; Fenech A; Borg J; Patrinos GP
Pharmacogenomics; 2012 Apr; 13(5):525-8. PubMed ID: 22462744
[TBL] [Abstract][Full Text] [Related]
16. Genomics and personalized medicine.
Sadee W
Int J Pharm; 2011 Aug; 415(1-2):2-4. PubMed ID: 21539903
[TBL] [Abstract][Full Text] [Related]
17. Lexical fields of predictive and personalized medicine.
Mathieu T; Bermont L; Boyer JC; Versuyft C; Evrard A; Cuvelier I; Couderc R; Peoc'h K;
Drug Metabol Drug Interact; 2013; 28(2):125-32. PubMed ID: 23740683
[TBL] [Abstract][Full Text] [Related]
18. Role of genomics on the path to personalized medicine.
Tremblay J; Hamet P
Metabolism; 2013 Jan; 62 Suppl 1():S2-5. PubMed ID: 23021037
[TBL] [Abstract][Full Text] [Related]
19. Personalized medicine and rescuing "unsafe" drugs with pharmacogenomics: a regulatory perspective.
Avery M
Food Drug Law J; 2010; 65(1):37-65, i-ii. PubMed ID: 24475534
[TBL] [Abstract][Full Text] [Related]
20. Institutional profile: The Carney Centre for Pharmacogenomics: a New Zealand focus for personalized medicine research.
Kennedy MA; Joyce PR; Begg EJ
Pharmacogenomics; 2012 Jun; 13(8):865-8. PubMed ID: 22676191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
